X4 Pharmaceuticals (XFOR) Net Cash Flow (2017 - 2025)
X4 Pharmaceuticals' (XFOR) quarterly Net Cash Flow came in at $147.4 million in Q4 2025, up 455.4% YoY from $26.5 million in Q4 2024, and up 384.37% on a QoQ basis from $30.4 million in Q3 2025.
X4 Pharmaceuticals (XFOR) Net Cash Flow (2017 - 2025) Analysis & Trends
X4 Pharmaceuticals (XFOR) has 9 years of Net Cash Flow data on file, last reported at $147.4 million in Q4 2025.
- Quarterly Net Cash Flow rose 455.4% year-over-year to $147.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $161.2 million (up 308.65% YoY) and the FY2025 annual result came in at $161.2 million, up 469.5% from the prior year.
- Net Cash Flow climbed to $147.4 million in Q4 2025, from $30.4 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $147.4 million in Q4 2025 to a low of -$52.8 million in Q3 2023.
- A 5-year average of $1.5 million and a median of -$15.4 million in 2022 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2022 — Net Cash Flow soared 654.31% — and 2023, when it plunged 261.51%.
- Tracing XFOR's Net Cash Flow over 5 years: stood at $5.5 million in 2021, then soared by 654.31% to $41.5 million in 2022, then slumped by 178.24% to -$32.5 million in 2023, then declined by 27.7% to -$41.5 million in 2024, then surged by 455.4% to $147.4 million in 2025.
- The last three Net Cash Flow figures came in at $147.4 million (Q4 2025), $30.4 million (Q3 2025), and -$1.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | X4 Pharmaceuticals | 533.17 Mn | 338.08 Mn | 7.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 147.42 Mn |
| Dec 31, 2025 | 147.42 Mn |
| Sep 30, 2025 | 30.44 Mn |
| Sep 30, 2025 | 30.44 Mn |
| Jun 30, 2025 | -1.19 Mn |
| Jun 30, 2025 | -1.19 Mn |
| Mar 31, 2025 | -15.51 Mn |
| Mar 31, 2025 | -15.51 Mn |
| Dec 31, 2024 | -41.48 Mn |
| Dec 31, 2024 | -41.48 Mn |
| Sep 30, 2024 | -49.96 Mn |
| Sep 30, 2024 | -49.96 Mn |
| Jun 30, 2024 | 53.12 Mn |
| Jun 30, 2024 | 53.12 Mn |
| Mar 31, 2024 | -38.92 Mn |
| Mar 31, 2024 | -38.92 Mn |
| Dec 31, 2023 | -32.48 Mn |
| Dec 31, 2023 | -32.48 Mn |
| Sep 30, 2023 | -52.75 Mn |
| Sep 30, 2023 | -52.75 Mn |